ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0496

A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease

David Patrick1, Justin van Beusecum1, Michelle Ormseth2, Leslie J. Crofford2, Sean Davies3, Sergey Dikalov1 and David Harrison1, 1Vanderbilt University Medical Center, Nashville, 2Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University, Nashville

Meeting: ACR Convergence 2020

Keywords: Cardiovascular, immunology, Monocytes/macrophages, Mouse Models, Lupus, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Etiology & Pathogenesis (0494–0498)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: In SLE, cardiovascular complications are a significant contributor to morbidity and death. Importantly, there is an increased prevalence of hypertension in SLE patients compared to healthy controls. We have identified a critical role of isolevuglandins (isoLGs) as activators of the immune system in essential hypertension. IsoLGs are peroxidized products of fatty acids that form as a result of reactive oxygen species. These isoLG adducts participate in the activation of T-cells and contributed. We hypothesize that isoLGs are important for the development of hypertension and systemic immune activation in SLE.

Methods: To determine the presence of isoLG’s in monocytes of human subjects we recruited 11 subjects with SLE and 10 controls subjects. IsoLG adduct accumulation within antigen presenting cells was performed by flow cytometry and mass spectrometry. Superoxide was measured by incubation with dihydroethidium and subsequent high performance liquid chromatography. Flow cytometry was performed with a single chain antibody that recognizes isoLG adducted lysine residues independent of the peptide backbone. CD11c+ and CD14+ monocytes were analyzed for the presence of isoLG adducts. To determine a causative role of isoLG adducts in immune activation and hypertension in SLE, we employed the B6.SLE123 and NZBWF1 mouse models of SLE. Animals were treated with the specific isoLG scavenger 2-hydroxybenzylamine (2-HOBA) or vehicle beginning at 7 weeks. Animals were sacrificed at 32 weeks of age and C57BL/6 and NZW were used as controls. Blood pressure was analyzed by radiotelemetry. Immune cell accumulation was determined by flow cytometry and the presence of anti-isoLG adduct antibodies was determined by a capture enzyme linked immunosobent assay (ELISA).

Results: By flow cytometry and mass spectrometry we found marked accumulation of isoLG adducts within CD11c+ and CD14+ antigen presenting cells in SLE subjects compared to control. This was accompanied by an increase in superoxide production in CD14+ monocytes. In animals, treatment with 2-HOBA attenuated blood pressure in both mouse models. Immune cell accumulation in primary and secondary lymphoid organs is significantly attenuated by 2-HOBA. Moreover, treatment with 2-HOBA reduced albuminuria and renal injury in the B6.SLE123 model of SLE as measured by urinary albumin/creatinine ratio and histologic scoring. Similarly, there is a significant reduction in bone marrow plasma cell accumulation and anti-double stranded DNA (anti-dsDNA) titers in treated animals. Finally we have detected anti-isoLG-adduct IgG in serum collected from both mouse models.

Conclusion: These studies define a critical role of isoLG adduct accumulation in both systemic immune activation and hypertension in SLE. Moreover, they suggest a potential therapeutic strategy for the treatment of SLE and associated cardiovascular disease.


Disclosure: D. Patrick, None; J. van Beusecum, None; M. Ormseth, None; L. Crofford, None; S. Davies, Metabolic Technologies Inc, 9; S. Dikalov, None; D. Harrison, None.

To cite this abstract in AMA style:

Patrick D, van Beusecum J, Ormseth M, Crofford L, Davies S, Dikalov S, Harrison D. A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-role-of-lipid-peroxidation-in-systemic-lupus-erythematosus-associated-cardiovascular-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-role-of-lipid-peroxidation-in-systemic-lupus-erythematosus-associated-cardiovascular-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology